Literature DB >> 5443170

Metabolic properties of IgG subclasses in man.

A Morell, W D Terry, T A Waldmann.   

Abstract

Metabolic properties of the four subclasses of human IgG were investigated by performing 47 turnover studies in individuals with normal IgG serum concentrations, as well as in patients with an increased level of one of the subclasses. Studies in 12 subjects with normal IgG serum concentration showed that the average biologic half-life of G(1), G(2), and G(4) was 21 days, while that of G(3) was only 7.1 days. Fractional catabolic rates of G(1), G(2), and G(4) were 6.9 to 8% of the intravascular pool per day. G(3), however, had a higher fractional catabolic rate, amounting to 16.8% of the intravascular pool per day. Distribution of the subclasses was such that the intravascular compartment contained 51-54% of the total body pools of G(1), G(2), and G(4), but 64% of the total body pool of G(3).The short survival and high fractional catabolic rate of G(3) is an inherent property of these molecules, and is not due to denaturation during isolation and radiolabeling. This was demonstrated by studies of a patient with a serum G(3)-myeloma protein. The survival of her own protein, separately labeled either in vivo with guanidoarginine-(14)C or in vitro with (125)I, was determined in the patient. Survivals of the in vivo and in vitro labeled proteins were identical.G(1) and G(3) serum concentrations and synthetic rates were determined. The mean serum concentration of G(1) was 6.8 mg/ml and that of G(3) was 0.7 mg/ml, while their synthetic rates were 25.4 and 3.4 mg/kg per day respectively. The low serum concentration of IgG(2) thus results from a combination of high catabolic and low synthetic rates. Studies in 10 patients with multiple myeloma showed that an elevated serum concentration of any IgG subclass was associated with shortened biologic half-life and increased fractional catabolic rate of all subclasses. The implications of this concentration-catabolism relationship are discussed. The serum concentration of nonmyeloma IgG was usually low in myeloma patients and the synthesis of nonmyeloma IgG was somewhat decreased, suggesting that low serum concentrations of nonmyeloma IgG result from decreased synthesis, as well as from an increased fractional catabolic rate.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5443170      PMCID: PMC322522          DOI: 10.1172/JCI106279

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.

Authors:  J L FAHEY; A G ROBINSON
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

2.  INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA.

Authors:  J L FAHEY; R SCOGGINS; J P UTZ; C F SZWED
Journal:  Am J Med       Date:  1963-11       Impact factor: 4.965

3.  QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES.

Authors:  J L FAHEY; E M MCKELVEY
Journal:  J Immunol       Date:  1965-01       Impact factor: 5.422

4.  Catabolism and distribution of gamma-globulin. A preliminary study with 131 I-labelled gammaglobulin.

Authors:  G BIRKE; S O LILJEDAHL; B OLHAGEN; L O PLANTIN; S AHLINDER
Journal:  Acta Med Scand       Date:  1963-05

5.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

6.  The C-terminal sequences of the heavy chains of human immunoglobulin G myeloma proteins of differing isotopes and allotypes.

Authors:  J W Prahl
Journal:  Biochem J       Date:  1967-12       Impact factor: 3.857

7.  Catabolism of human gamma-G immunoglobulins of different heavy chain subclasses. II. Catabolism of gamma-G myeloma proteins in heterologous species.

Authors:  H L Spiegelberg; H M Grey
Journal:  J Immunol       Date:  1968-10       Impact factor: 5.422

8.  Use of insoluble antibody for quantitative determination of small amounts of immunoglobulin.

Authors:  D Mann; H Granger; J L Fahey
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

9.  The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments.

Authors:  R D Wochner; W Strober; T A Waldmann
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

10.  Heavy chain subclasses of human gamma G-globulin. Serum distribution and cellular localization.

Authors:  G M Bernier; R E Ballieux; K T Tominaga; F W Putnam
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

View more
  168 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.

Authors:  Bo Zhou; Birong Lin; Jing Li; Weizhu Qian; Sheng Hou; Dapeng Zhang; Geng Kou; Bohua Li; Hao Wang; Yongchuan Chen; Yajun Guo
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

3.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

Review 4.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 5.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

Review 6.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

7.  Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism.

Authors:  H M Chapel; M Lee
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

8.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

9.  Human fibronectin metabolism.

Authors:  B A Pussell; P W Peake; M A Brown; J A Charlesworth
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans.

Authors:  Jiang Ma; Wei Zhang; Yisheng He; Lin Zhu; Chunyuan Zhang; Jia Liu; Yang Ye; Yuzheng Zhuge; Ge Lin
Journal:  Arch Toxicol       Date:  2020-11-18       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.